Ricin vaccine - Soligenix

Drug Profile

Ricin vaccine - Soligenix

Alternative Names: recombinant ricin toxin A-chain subunit - Soligenix; Ricin toxin vaccine - Soligenix; Ricin vaccine - DOR BioPharma; RiVax

Latest Information Update: 10 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer Soligenix
  • Class Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ricin poisoning
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Ricin poisoning

Most Recent Events

  • 09 Jul 2018 Soligenix receives patent allowance for Ricin toxin vaccine in Europe and Canada
  • 09 Jul 2018 Soligenix plans a phase II safety and immunogenicity trial for Ricin poisoning in the second half of 2018
  • 22 Mar 2018 Ricin vaccine - Soligenix receives Orphan Drug status for Ricin poisoning (Prevention) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top